Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Presence of Estrogen Metabolites in Urine Predicts Cancer

By Labmedica staff writers
Posted on 14 Feb 2008
Estrogens can initiate cancer when natural mechanisms of protection do not work properly in the body, allowing estrogen metabolites to react with DNA. More...
A simple test can determine the presence of the estrogen metabolites in urine and be an indication of breast and prostate cancer risk.

Estrogen metabolites react predominantly with the first two DNA bases, adenine and guanine, to form estrogen-DNA adducts. The resulting damage generated by the reaction can give rise to mutations that eventually initiate cancer. The important estrogen-DNA adducts spontaneously fall out of the DNA, leaving behind gaps that generate cancer-initiating mutations. The estrogen-DNA adducts eventually make their way out of cells and are excreted in urine.

The screening test developed by scientists analyzes estrogen metabolite profiles in humans and simultaneously associate the profile with risk of getting breast cancer. A one-ounce sample of urine is tested using tandem mass spectrometry, which analyzes about 40 estrogen-related compounds, including estrogen-DNA adducts.

Scientists analyzed estrogen-DNA from 46 women with normal risk for breast cancer, 12 women at high risk of developing breast cancer, and 17 women diagnosed with breast cancer. They found women at high risk of breast cancer and the women with breast cancer had significantly higher levels of the estrogen-DNA adducts in their urine samples, while the women with normal risk for breast cancer had low levels.

The University of Nebraska Medical Center (UNMC; Omaha, NE, USA) team stated that there is a single initiating step in cancer development and that cancer can be assessed, prevented, and detected by understanding this common mechanism.

Eleanor Rogan, Ph.D., who took part in the study, said, "We have found the first step that starts a cell down the road to becoming a cancer cell. By preventing this first step from happening, we think we can stop the development of breast or prostate cancer. The combination of an early detection test for cancer risk with administration of preventing agents should enable us to significantly reduce the number of women and men that develop breast or prostate cancer.”

"If these protections are insufficient, due to genetic, lifestyle, or environmental influences, we think cancer can result,” Dr. Cavalieri said. "Now that we have the basic knowledge about this unifying mechanism of cancer initiation, we have a greater sense of urgency to assess people at risk, and at the same time, begin studies of prevention by using specific natural compounds.”

The findings were published in the December 2008 issue of the International Journal of Cancer. The study involved investigators at the University of Nebraska Medical Center (Omaha, NE, USA), Mayo Clinic (Scottsdale, AZ, USA), and the Italian National Cancer Institute (Naples, Italy).


Related Links:
University of Nebraska Medical Center
Mayo Clinic

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Collection and Transport System
PurSafe Plus®
Gold Member
Hematology Analyzer
Medonic M32B
New
Gold Member
Automatic CLIA Analyzer
Shine i9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Elecsys Dengue Ag assay is intended for the in vitro qualitative detection of dengue virus NS1 antigen in human serum and plasma (Photo courtesy of Roche)

Automated Test Distinguishes Dengue from Acute Fever-Causing Illnesses In 18 Minutes

Dengue fever remains the most common mosquito-borne viral infection worldwide, posing a major public health challenge as global cases continue to surge. In 2024 alone, more than 14.6 million infections... Read more

Hematology

view channel
Image: A schematic illustrating the coagulation cascade in vitro (Photo courtesy of Harris, N., 2024)

ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners

Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read more

Microbiology

view channel
Image: EBP and EBP plus have received FDA 510(k) clearance and CE-IVDR Certification for use on the BD COR system (Photo courtesy of BD)

High-Throughput Enteric Panels Detect Multiple GI Bacterial Infections from Single Stool Swab Sample

Gastrointestinal (GI) infections are among the most common causes of illness worldwide, leading to over 1.7 million deaths annually and placing a heavy burden on healthcare systems. Conventional diagnostic... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.